Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15944143 | 0.89 | SLC6A2 (0.38) | CYP19A1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL16174529 | 0.88 | CYP19A1 (0.38) | CYP19A1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL16174528 | 0.86 | CYP19A1 (0.39) | CYP19A1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL14589097 | 0.84 | CYP19A1 (0.39) | CYP19A1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL16174526 | 0.84 | MGLL (0.33) | ALDH1A1 | |
| SCHEMBL27269423 | 0.82 | MGLL (0.35) | ALDH1A1 | |
| SCHEMBL13071687 | 0.82 | CYP19A1 (0.35) | PRMT6CYP19A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12754941 | 0.81 | — | — | |
| SCHEMBL23369332 | 0.81 | CYP19A1 (0.37) | CYP19A1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL19981935 | 0.81 | ALDH1A1 (0.32) | CYP19A1SMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023118599-A1 | IMPLANTABLE DEVICE COMPRISING A HYDROGEL | ADOCIA (FR) | 2023-06-29 | — | — | WO | disclosed |
| EP-4190361-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG, AND PREPARATION METHOD THERFOR AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-06-07 | — | — | EP | disclosed |
| EP-4190360-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG SYNERGIST, PREPARATION METHOD THEREFOR, AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022148887-A1 | HYDROGELS FOR CELL THERAPY | ADOCIA (FR) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022022360-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG, AND PREPARATION METHOD THERFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2022-02-03 | — | — | WO | disclosed |
| EP-3313884-B9 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN INC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3313884-B1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN INC (US) | 2020-11-18 | — | — | EP | disclosed |
| WO-2020223351-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD123 IMMUNOCONJUGATES | IMMUNOGEN, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2018119196-A1 | IMMUNOCONJUGATES TARGETING ADAM9 AND METHODS OF USE THEREOF | IMMUNOGEN, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20170029514-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20090017004-A1 | POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID | ENZON PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090017004-A1 | POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID | ENZON PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2009009712-A1 | POLYMERIC DRUG DELIVERY SYSTEM CONTAINING A MULTI-SUBSTITUTED AROMATIC MOIETY | ENZON PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008070477-A9 | POLYMERIC SHORT INTERFERING RNA CONJUGATES | ENZON PHARMACEUTICALS INC (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008034123-A2 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008034122-A2 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008034124-A2 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008034119-A2 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008034120-A2 | LYSINE-BASED POLYMERIC LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-0867190-B1 | CYTOTOXIN COMPLEXES COMPRISING DIPEPTIDES | KYOWA HAKKO KOGYO KK (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017004-A1 | POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID | AADAC, ACSS2, ANXA6 | CARM1 2622/4885PRMT6 1990/4885PRMT8 3316/4885 |
| US-20170029514-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IL23R, CD22, IL2RA | CARM1 3407/4885PRMT6 3305/4885PRMT8 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.